IL148975A0 - Novel cyclopropanes as cprp antagonists, medicaments containing said compounds and method for the production thereof - Google Patents

Novel cyclopropanes as cprp antagonists, medicaments containing said compounds and method for the production thereof

Info

Publication number
IL148975A0
IL148975A0 IL14897500A IL14897500A IL148975A0 IL 148975 A0 IL148975 A0 IL 148975A0 IL 14897500 A IL14897500 A IL 14897500A IL 14897500 A IL14897500 A IL 14897500A IL 148975 A0 IL148975 A0 IL 148975A0
Authority
IL
Israel
Prior art keywords
cprp
cyclopropanes
antagonists
novel
compounds
Prior art date
Application number
IL14897500A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of IL148975A0 publication Critical patent/IL148975A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
IL14897500A 1999-10-29 2000-10-21 Novel cyclopropanes as cprp antagonists, medicaments containing said compounds and method for the production thereof IL148975A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19952147A DE19952147A1 (de) 1999-10-29 1999-10-29 Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
PCT/EP2000/010391 WO2001032648A1 (fr) 1999-10-29 2000-10-21 Nouveaux cyclopropanes utilises comme antagonistes de cgrp, medicaments contenant lesdits composes et procedes permettant de les preparer

Publications (1)

Publication Number Publication Date
IL148975A0 true IL148975A0 (en) 2002-11-10

Family

ID=7927315

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14897500A IL148975A0 (en) 1999-10-29 2000-10-21 Novel cyclopropanes as cprp antagonists, medicaments containing said compounds and method for the production thereof

Country Status (27)

Country Link
US (2) US20030139417A1 (fr)
EP (1) EP1228059B1 (fr)
JP (1) JP3869721B2 (fr)
KR (1) KR20020047290A (fr)
CN (1) CN1177844C (fr)
AT (1) ATE301117T1 (fr)
AU (1) AU781856B2 (fr)
BG (1) BG106638A (fr)
BR (1) BR0015147A (fr)
CA (1) CA2387134C (fr)
CZ (1) CZ20021812A3 (fr)
DE (2) DE19952147A1 (fr)
EA (1) EA005137B1 (fr)
EE (1) EE200200220A (fr)
HK (1) HK1051858A1 (fr)
HR (1) HRP20020373A2 (fr)
HU (1) HUP0203496A3 (fr)
IL (1) IL148975A0 (fr)
MX (1) MXPA02004119A (fr)
NO (1) NO20021799L (fr)
NZ (1) NZ518698A (fr)
PL (1) PL354715A1 (fr)
SK (1) SK7282002A3 (fr)
TR (1) TR200201168T2 (fr)
WO (1) WO2001032648A1 (fr)
YU (1) YU30902A (fr)
ZA (1) ZA200203256B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US20040063735A1 (en) * 2002-06-05 2004-04-01 Chaturvedula Prasad V. Calcitonin gene related peptide receptor antagonists
EP1689493A4 (fr) 2003-12-05 2008-04-23 Bristol Myers Squibb Co Antagonistes du recepteur peptidique lie au gene de la calcitonine
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
JP2008512459A (ja) * 2004-09-09 2008-04-24 メルク エンド カムパニー インコーポレーテッド アリールスピロラクタムｃｇｒｐ受容体拮抗薬
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
AU2006316627A1 (en) * 2005-11-18 2007-05-31 Merck Sharp & Dohme Corp. Spirolactam aryl CGRP receptor antagonists
WO2009034029A2 (fr) * 2007-09-07 2009-03-19 Boehringer Ingelheim International Gmbh Nouveaux composés
BRPI0817835A2 (pt) 2007-10-18 2015-03-31 Boehringer Ingelheim Int Antagonistas cgrp
EP2065381A1 (fr) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG Antagonistes du CGRP
WO2009065919A2 (fr) 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Nouveaux composés
US9315449B2 (en) * 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2013151707A1 (fr) * 2012-04-05 2013-10-10 Chdi Foundation, Inc. Inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci
JP6449893B2 (ja) 2013-09-26 2019-01-09 シーエイチディーアイ ファウンデーション，インコーポレーテッド キヌレニン−３−モノオキシゲナーゼ阻害薬、医薬組成物、及びこれらの使用方法
WO2015047982A2 (fr) 2013-09-26 2015-04-02 Chdi Foundation, Inc. Inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques et procédés d'utilisation de ces compositions
JP2019040859A (ja) * 2017-08-22 2019-03-14 株式会社エンプラス 発光装置、面光源装置および光束制御部材
CN114957145B (zh) * 2022-04-14 2023-07-18 浙江师范大学 一种1,2,4-苯并三嗪衍生物及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655667A (en) * 1968-04-04 1972-04-11 Smith Kline French Lab 1-(2-benzoylcyclopropylmethyl)-4-phenylpiperazines
US3873707A (en) * 1972-10-02 1975-03-25 Robins Co Inc A H 1-Cyclopropyl-3-mono-(and 2,3-di) substituted-1-propanones in compositions and method for treating pain
FR2729855A1 (fr) 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
JP3048067B2 (ja) 1995-12-15 2000-06-05 ノボ ノルディスク アクティーゼルスカブ 新規方法
AU4261697A (en) * 1996-09-09 1998-03-26 Smithkline Beecham Corporation Compounds and methods
DE59711622D1 (de) 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
BR9809147A (pt) 1997-05-22 2000-08-01 Searle & Co Composto pirazol substituìdo, composição farmacêutica, processos para tratar um distúrbio mediado por tnf, um distúrbio mediado por quinase p38, inflamação e artrite, e, para preparar pirazóis
AU2825999A (en) * 1998-03-17 1999-10-11 Novo Nordisk A/S Novel heterocyclic compounds
DE19911039A1 (de) 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CN1344266A (zh) * 1999-03-26 2002-04-10 阿斯特拉曾尼卡有限公司 新的化合物
DE19937304C2 (de) 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
US6696418B1 (en) * 1999-09-01 2004-02-24 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
TWI227231B (en) * 2000-07-12 2005-02-01 Novartis Ag 4-benzoyl-piperidine derivatives for treating conditions mediated by CCR-3
US6642256B2 (en) * 2000-12-21 2003-11-04 Warner-Lambert Company Llc Piperidine derivatives as subtype selective N-Methyl-D-Aspartate antagonists
JP2005511560A (ja) * 2001-11-01 2005-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド コレステロール生合成経路の変調
US6977265B2 (en) * 2001-11-30 2005-12-20 Roche Palo Alto Llc Piperidine CCR-3 receptor antagonists
US7026312B2 (en) * 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof

Also Published As

Publication number Publication date
EA005137B1 (ru) 2004-12-30
MXPA02004119A (es) 2003-10-06
CN1387526A (zh) 2002-12-25
CZ20021812A3 (cs) 2002-08-14
TR200201168T2 (tr) 2002-08-21
BR0015147A (pt) 2002-07-16
EE200200220A (et) 2003-06-16
US20050267137A1 (en) 2005-12-01
PL354715A1 (en) 2004-02-09
HUP0203496A2 (hu) 2003-02-28
ZA200203256B (en) 2003-04-10
EP1228059B1 (fr) 2005-08-03
JP2003513087A (ja) 2003-04-08
NZ518698A (en) 2004-12-24
JP3869721B2 (ja) 2007-01-17
WO2001032648A1 (fr) 2001-05-10
KR20020047290A (ko) 2002-06-21
DE19952147A1 (de) 2001-05-03
EP1228059A1 (fr) 2002-08-07
CA2387134A1 (fr) 2001-05-10
US7407963B2 (en) 2008-08-05
NO20021799D0 (no) 2002-04-17
NO20021799L (no) 2002-04-17
CN1177844C (zh) 2004-12-01
HRP20020373A2 (en) 2003-10-31
AU7921300A (en) 2001-05-14
CA2387134C (fr) 2008-07-08
DE50010886D1 (de) 2005-09-08
HUP0203496A3 (en) 2004-01-28
BG106638A (bg) 2003-01-31
US20030139417A1 (en) 2003-07-24
YU30902A (sh) 2005-07-19
EA200200447A1 (ru) 2002-10-31
AU781856B2 (en) 2005-06-16
SK7282002A3 (en) 2002-11-06
ATE301117T1 (de) 2005-08-15
HK1051858A1 (en) 2003-08-22

Similar Documents

Publication Publication Date Title
IL148975A0 (en) Novel cyclopropanes as cprp antagonists, medicaments containing said compounds and method for the production thereof
MY138086A (en) Novel urea derivative as vanilloid receptor-1 antagonist
MY140057A (en) Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine
BG105925A (en) Novel tricyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
EP1619192A3 (fr) Composes azapolycycliques a fusion aryle
MY136430A (en) N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
GB0013737D0 (en) Novel compounds
EP0282959A3 (fr) 9-Amino-tétrahydro-acridines substitués et composés apparentés, leur procédé de préparation et leur utilisation comme médicaments
CA2395541A1 (fr) Nouveaux piperidines substituees, medicaments contenant ces composes et procedes permettant de les preparer
MY136269A (en) Novel diphenylazetidinone, process for its preparation, medicaments comprising this compound and their use
BG106932A (en) Novel compounds having hypolipedemic and hypocholesteremic activities, processes for their preparation and pharmaceutical compositions containing them
WO2001010860A3 (fr) Derives de quinazolinone et d'azaquinazolinone
RS20050047A (en) Indoline derivatives substituted in position 6,production and use thereof as medicaments
CA2392057A1 (fr) Sels de calcium de derives de 1,5-benzodiazepine, procede de fabrication de ces sels et medicaments les renfermant
HU910748D0 (en) New substituted amine compounds and process for producing them
WO2002072567A3 (fr) Nouveaux composes heterocycliques utiles dans le traitement des troubles allergiques inflammatoires; procede de leur preparation et compositions pharmaceutiques les contenant
ATE307809T1 (de) Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
PL338348A1 (en) Thiazolobenzenoheterocyclic compounds, their production and drugs containing them
WO2005035528A3 (fr) Nouveaux composes triazoliques, leur procede de preparation et compositions pharmaceutiques les contenant
DE60335960D1 (de) 1,2,4-triazolderivat, verfahren zu dessenherstellung, und dieses enthaltende pharmazeutische zusammensetzung
MXPA04002784A (es) Sales farmaceuticamente aceptables de 20(s)-camptotecinas.
TW200509889A (en) Aniline derivatives
MXPA04001852A (es) Uso de sistemas indan-1-ol c2-sustituidas para la produccion de medicamentos para la profilaxis o tratamiento de obesidad.
MXPA04001856A (es) Indan-1-oles c2-sustituidos y sus derivados, metodo para su produccion y su uso como medicamentos.
HK1038017A1 (en) Novel 2,3,3a,4,9,9a hexahydro-8-hydroxy-1h-benzÄfÜindoles, a method for the production thereof, and their use as medicaments.